Longeveron Inc.
LGVNDrugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
This month
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
Lomecel-B medicinal signaling cells Phase 2 Est. Readout
Primary completion for Lomecel-B medicinal signaling cells trial (NCT04925024) in Hypoplastic Left Heart Syndrome
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Lomecel-B medicinal signaling cells
Hypoplastic Left Heart Syndrome
Fluzone High Dose Vaccine
Aging Frailty
Allogeneic MSC
Mild Alzheimer's Disease
Longeveron Mesenchymal Stem Cells (LMSCs)
Aging Frailty
Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Frailty
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lomecel-B medicinal signaling cells | Phase 2 | Hypoplastic Left Heart Syndrome | - | - |
Fluzone High Dose Vaccine | Phase 2 | Aging Frailty | - | - |
Allogeneic MSC | Phase 2 | Mild Alzheimer's Disease | - | - |
Longeveron Mesenchymal Stem Cells (LMSCs) | Phase 2 | Aging Frailty | - | - |
Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) | Phase 2 | Frailty | - | - |